Výsledky vyhľadávania - "Nivolumab/administration & dosage"

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Autori: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey a ďalší

Prispievatelia: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey a ďalší

Zdroj: Acta Oncologica, Vol 64 (2025)
Acta oncologica
ACTA ONCOLOGICA

Predmety: Male, Immune Checkpoint Inhibitors/administration & dosage, Radiology, Nuclear Medicine and Imaging, Time Factors, Oncologie, THERAPY, Carcinoma, Renal Cell/secondary, immune checkpoint inhibitors, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Ipilimumab/administration & dosage, Human health sciences, Kidney Neoplasms/mortality, Immune Checkpoint Inhibitors, RC254-282, Aged, 80 and over, OUTCOMES, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Carcinoma, Renal Cell/pathology, Hematology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Kidney Neoplasms, Progression-Free Survival, Renal cell carcinoma, Nivolumab/administration & dosage, treatment discontinuation, Carcinoma, Renal Cell/mortality, Kidney Neoplasms/drug therapy, Nivolumab, optimal treatment duration, Oncology, Female, Life Sciences & Biomedicine, Adult, DISCONTINUATION, Sciences de la santé humaine, Kidney Neoplasms/pathology, Immune Checkpoint Inhibitors/adverse effects, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Carcinoma, Renal Cell, Retrospective Studies, Aged, Science & Technology, Duration of Therapy, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, MELANOMA PATIENTS, Carcinoma, Renal Cell/drug therapy, Human medicine, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://doaj.org/article/f0b66be9934249d38e034df42f696b62
https://hdl.handle.net/2268/335276
https://doi.org/10.2340/1651-226X.2025.43876
https://repository.uantwerpen.be/docstore/d:irua:30312
https://hdl.handle.net/10067/2161490151162165141
http://hdl.handle.net/1942/46632
http://hdl.handle.net/1854/LU-01K3QQRTE94KZYP1CX1X0WZ5CD
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD/file/01K42SV66F3YD38FGWT899GJ86
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD
http://doi.org/10.2340/1651-226x.2025.43876

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Autori: Peters, Solange Paz-Ares, Luis G. Reck, Martin a ďalší

Prispievatelia: Peters, Solange Paz-Ares, Luis G. Reck, Martin a ďalší

Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 20, no. 1, pp. 94-108

Predmety: PD-L1, Nivolumab, Non–small cell lung cancer, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Nivolumab/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Lung Neoplasms/metabolism, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Ipilimumab/administration & dosage, Male, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Aged, Adult, Survival Rate, Aged, 80 and over, Follow-Up Studies, Immunotherapy, Ipilimumab

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39369790
http://hdl.handle.net/10261/390933
https://api.elsevier.com/content/abstract/scopus_id/85208360083
https://serval.unil.ch/resource/serval:BIB_89D370D6F09D.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_89D370D6F09D
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_89D370D6F09D7

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Autori: Thierry André Elena Elez Eric Van Cutsem a ďalší

Zdroj: New England Journal of Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)

Predmety: Adult, Aged, 80 and over, Male, Gastroenterology, Colorectal Neoplasms/drug therapy, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Hematology/Oncology, DNA Mismatch Repair, Ipilimumab, Progression-Free Survival, Nivolumab/administration & dosage, Young Adult, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Female, Microsatellite Instability, Ipilimumab/administration & dosage, Colorectal Neoplasms, Gastrointestinal Tract Cancer, Treatments in Oncology, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39602630
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14241

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Autori: N.M. Tannir L. Albigès D.F. McDermott a ďalší

Prispievatelia: N.M. Tannir L. Albigès D.F. McDermott a ďalší

Zdroj: Tannir, N M, Albigès, L, McDermott, D F, Burotto, M, Choueiri, T K, Hammers, H J, Barthélémy, P, Plimack, E R, Porta, C, George, S, Donskov, F, Atkins, M B, Gurney, H, Kollmannsberger, C K, Grimm, M O, Barrios, C, Tomita, Y, Castellano, D, Grünwald, V, Rini, B I, Jiang, R, Desilva, H, Fedorov, V, Lee, C W & Motzer, R J 2024, 'Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma : extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial', Annals of Oncology, vol. 35, no. 11, pp. 1026-1038. https://doi.org/10.1016/j.annonc.2024.07.727

Predmety: Male, Adult, Renal Cell/drug therapy, Medizin, long-term follow-up, Sunitinib/administration & dosage, dual checkpoint inhibition, Antineoplastic Combined Chemotherapy Protocols, Sunitinib, Humans, Ipilimumab/administration & dosage, ipilimumab, Carcinoma, Renal Cell, Aged, Carcinoma, advanced renal cell carcinoma, Middle Aged, phase III, Ipilimumab, CheckMate 214, Kidney Neoplasms, Progression-Free Survival, Nivolumab, ipilimumab, Nivolumab/administration & dosage, Kidney Neoplasms/drug therapy, Nivolumab, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39098455

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Autori: Morihito Okada Ken Kato Byoung Chul Cho a ďalší

Prispievatelia: Morihito Okada Ken Kato Byoung Chul Cho a ďalší

Zdroj: Clin Cancer Res

Predmety: Programmed Cell Death 1 Receptor / therapeutic use, Esophageal Neoplasms, Programmed Cell Death 1 Receptor, Esophageal Neoplasms* / drug therapy, Nivolumab / administration & dosage, 3. Good health, Nivolumab/administration & dosage, Clinical Trials: Immunotherapy, Esophageal Squamous Cell Carcinoma/drug therapy, Nivolumab, Programmed Cell Death 1 Receptor/therapeutic use, Esophageal Squamous Cell Carcinoma* / drug therapy, Humans, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms/drug therapy, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35294546
https://portal.findresearcher.sdu.dk/da/publications/6835f252-94d6-43c0-ab52-b5133b8191fb
https://doi.org/10.1158/1078-0432.CCR-21-0985

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Autori: Doki, Yuichiro Ajani, Jaffer A Kato, Ken a ďalší

Prispievatelia: Doki, Yuichiro Ajani, Jaffer A Kato, Ken a ďalší

Zdroj: Doki, Y, Ajani, J A, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, Ogata, T, Kawakami, H, Hsu, C H, Adenis, A, El Hajbi, F, Di Bartolomeo, M, Braghiroli, M I, Holtved, E, Ostoich, S A, Kim, H R, Ueno, M, Mansoor, W, Yang, W C, Liu, T, Bridgewater, J, Makino, T, Xynos, I, Liu, X, Lei, M, Kondo, K, Patel, A, Gricar, J, Chau, I, Kitagawa, Y & CheckMate 648 Trial Investigators 2022, ' Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma ', The New England Journal of Medicine, vol. 386, no. 5, pp. 449-462 . https://doi.org/10.1056/NEJMoa2111380

Predmety: Adult, Male, Squamous Cell/drug therapy, Immune Checkpoint Inhibitors/administration & dosage, Esophageal Neoplasms, B7-H1 Antigen/antagonists & inhibitors, B7-H1 Antigen, Carcinoma, Squamous Cell/drug therapy, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Ipilimumab/administration & dosage, Immune Checkpoint Inhibitors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carcinoma, CheckMate 648 Trial Investigators, Middle Aged, Ipilimumab, Survival Analysis, Progression-Free Survival, Nivolumab/administration & dosage, 3. Good health, Nivolumab, Squamous Cell, Carcinoma, Squamous Cell, Female, Esophageal Neoplasms/drug therapy

Popis súboru: Print; application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35108470
https://portal.findresearcher.sdu.dk/da/publications/76f3939c-aaec-43dc-b929-d332bb705979
https://discovery-pp.ucl.ac.uk/id/eprint/10143133/

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Autori: Owonikoko, Taofeek Park, Keunchil Govindan, Ramaswamy a ďalší

Prispievatelia: Owonikoko, Taofeek Park, Keunchil Govindan, Ramaswamy a ďalší

Zdroj: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
Journal of clinical oncology, vol. 39, no. 12, pp. 1349-1359

Predmety: Adult, Male, Lung Neoplasms, [SDV.IMM] Life Sciences [q-bio]/Immunology, Neoplasias pulmonares, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Otros calificadores::Otros calificadores::/uso terapéutico, Lung Neoplasms / drug therapy, Lung Neoplasms / mortality, Quimioteràpia combinada, 03 medical and health sciences, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma pulmonar de células pequeñas, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Ipilimumab / administration & dosage, Humans, Nivolumab / adverse effects, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Small Cell Lung Carcinoma, Aged, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Mutación, Small Cell Lung Carcinoma / mortality, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, ORIGINAL REPORTS, Toxicidad, Middle Aged, Nivolumab / administration & dosage, Small Cell Lung Carcinoma / drug therapy, Ipilimumab, Small Cell Lung Carcinoma, 3. Good health, Nivolumab, Ipilimumab / adverse effects, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Supervivencia sin progresión, Female, Quimioterapia, Pulmons - Càncer - Tractament

Popis súboru: application/pdf

Prístupová URL adresa: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02212
https://pubmed.ncbi.nlm.nih.gov/33683919
https://hdl.handle.net/11351/7760
http://hdl.handle.net/10668/17328
https://ascopubs.org/doi/10.1200/JCO.20.02212
https://europepmc.org/article/MED/33683919
https://profiles.wustl.edu/en/publications/nivolumab-and-ipilimumab-as-maintenance-therapy-in-extensive-dise
https://pubmed.ncbi.nlm.nih.gov/33683919/
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02212
https://snucm.elsevierpure.com/en/publications/nivolumab-and-ipilimumab-as-maintenance-therapy-in-extensive-dise
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_78F0D04B7BA31
https://serval.unil.ch/notice/serval:BIB_78F0D04B7BA3
https://hdl.handle.net/10668/17328
https://inria.hal.science/hal-03526410v1
https://doi.org/10.1200/jco.20.02212

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Autori: Tétu, P. Mangana, J. Dummer, R. a ďalší

Predmety: Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies, Humans, Ipilimumab/administration & dosage, Melanoma/drug therapy, Melanoma/pathology, Nivolumab/administration & dosage, Prognosis, Retrospective Studies, Survival Rate

Relation: European Journal of Cancer; https://iris.unil.ch/handle/iris/60408; serval:BIB_4C2D9AD34505; 000428617300018

Dostupnosť: https://iris.unil.ch/handle/iris/60408
https://doi.org/10.1016/j.ejca.2018.01.062

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

Autori: Pires da Silva, I. Ahmed, T. Reijers, ILM a ďalší

Predmety: Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Humanized/adverse effects, Cohort Studies, Drug Resistance, Neoplasm/genetics, Neoplasm/immunology, Female, Humans, Immune Checkpoint Inhibitors/administration & dosage, Immune Checkpoint Inhibitors/adverse effects, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Male, Melanoma/drug therapy, Melanoma/genetics, Melanoma/immunology, Melanoma/pathology, Middle Aged, Neoplasm Metastasis, Nivolumab/administration & dosage, Nivolumab/adverse effects, Positron Emission Tomography Computed Tomography, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Programmed Cell Death 1 Receptor/genetics, Progression-Free Survival, Retrospective Studies

Relation: The Lancet Oncology; https://iris.unil.ch/handle/iris/43471; serval:BIB_001DC1DD3B64; 000657432100058

Dostupnosť: https://iris.unil.ch/handle/iris/43471
https://doi.org/10.1016/S1470-2045(21)00097-8

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Autori: Grover, P. Lo, S.N. Li, I. a ďalší

Predmety: Humans, Melanoma/drug therapy, Melanoma/pathology, Melanoma/mortality, Female, Male, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Skin Neoplasms/mortality, Middle Aged, Retrospective Studies, Neoplasm Staging, Aged, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Nivolumab/administration & dosage, Antibodies, Monoclonal, Humanized/administration & dosage, Pyrimidinones/administration & dosage, Oximes/administration & dosage, Pyridones/administration & dosage, Imidazoles/administration & dosage, Adult, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Immune Checkpoint Inhibitors/therapeutic use, Melanoma, Cutaneous Malignant

Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/263693; serval:BIB_5701ED2CA755

Dostupnosť: https://iris.unil.ch/handle/iris/263693
https://doi.org/10.1016/j.annonc.2025.03.021

IL-32γ potentiates tumor immunity in melanoma.

Autori: Gruber, T. Kremenovic, M. Sadozai, H. a ďalší

Predmety: Animals, Antibodies, Monoclonal, Humanized/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Apoptosis, Biomarkers, Tumor/genetics, Tumor/metabolism, Cell Proliferation, Cohort Studies, Dendritic Cells/immunology, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Interleukins/genetics, Interleukins/metabolism, Lymphocytes/immunology, Macrophages/immunology, Male, Melanoma/drug therapy, Melanoma/immunology, Melanoma/metabolism, Melanoma/pathology, Mice, Inbred BALB C, Inbred C57BL, Nivolumab/administration & dosage

Popis súboru: application/pdf

Relation: JCI Insight; https://iris.unil.ch/handle/iris/236790; serval:BIB_EAB77059FBB6; 000573668600003

Dostupnosť: https://iris.unil.ch/handle/iris/236790
https://doi.org/10.1172/jci.insight.138772

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Autori: Hellmann, M.D. Paz-Ares, L. Bernabe Caro, R. a ďalší

Predmety: Adult, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/metabolism, Non-Small-Cell Lung/mortality, Female, Humans, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Lung Neoplasms/drug therapy, Lung Neoplasms/metabolism, Lung Neoplasms/mortality, Male, Middle Aged, Nivolumab/administration & dosage, Nivolumab/adverse effects, Survival Analysis

Relation: New England Journal of Medicine; https://iris.unil.ch/handle/iris/202270; serval:BIB_9D16DE496DBE; 000505218800006

Dostupnosť: https://iris.unil.ch/handle/iris/202270
https://doi.org/10.1056/NEJMoa1910231

Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.

Autori: Schmid, S. Mauti, L.A. Friedlaender, A. a ďalší

Predmety: Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Female, Follow-Up Studies, Humans, Immunotherapy/mortality, Ipilimumab/administration & dosage, Lung Neoplasms/drug therapy, Lung Neoplasms/immunology, Lung Neoplasms/mortality, Lung Neoplasms/pathology, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Local/immunology, Local/mortality, Local/pathology, Nivolumab/administration & dosage, Prognosis, Retrospective Studies, Small Cell Lung Carcinoma/drug therapy, Small Cell Lung Carcinoma/immunology, Small Cell Lung Carcinoma/mortality

Relation: Cancer Immunology, Immunotherapy; https://iris.unil.ch/handle/iris/202157; serval:BIB_9C822C4B4241; 000527516900002

Dostupnosť: https://iris.unil.ch/handle/iris/202157
https://doi.org/10.1007/s00262-020-02565-0

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

Autori: Chalabi, M. Verschoor, Y.L. Tan, P.B. a ďalší

Predmety: Adult, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Colonic Neoplasms/drug therapy, Colonic Neoplasms/genetics, Colonic Neoplasms/pathology, Colonic Neoplasms/surgery, Disease-Free Survival, DNA Mismatch Repair, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Ipilimumab/therapeutic use, Neoadjuvant Therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Nivolumab/therapeutic use, Time-to-Treatment, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Immunological/therapeutic use, Netherlands, Young Adult

Relation: New England Journal of Medicine; https://iris.unil.ch/handle/iris/174715; serval:BIB_6BBA7AFF15CD; 001265114100004

Dostupnosť: https://iris.unil.ch/handle/iris/174715
https://doi.org/10.1056/NEJMoa2400634

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.

Autori: Zezza, M. Kosinski, C. Mekoguem, C. a ďalší

Predmety: Acute Disease, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Diabetes Mellitus, Type 1/chemically induced, Type 1/diagnosis, Type 1/pathology, Female, Humans, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Male, Melanoma/drug therapy, Melanoma/pathology, Middle Aged, Nivolumab/administration & dosage, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Autoimmune adverse events, Endocrinopathies, Immune checkpoint inhibitor, Type 1 diabetes

Popis súboru: application/pdf

Relation: BMC Endocrine Disorders; https://iris.unil.ch/handle/iris/153712; serval:BIB_CB7AD473C23D; 000511656300001

Dostupnosť: https://iris.unil.ch/handle/iris/153712
https://doi.org/10.1186/s12902-019-0467-z

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.

Autori: Pillonel, V. Dunet, V. Hottinger, A.F. a ďalší

Predmety: Adult, Antineoplastic Agents, Immunological/administration & dosage, Immunological/adverse effects, Asymptomatic Diseases, Demyelinating Diseases/diagnosis, Demyelinating Diseases/etiology, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Melanoma/complications, Melanoma/diagnosis, Melanoma/drug therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Remission, Spontaneous, CNS demyelination, Immune checkpoint inhibitors, Immune related adverse events, Metastatic melanoma, Neurological toxicities, Nivolumab

Popis súboru: application/pdf

Relation: Journal for ImmunoTherapy of Cancer; https://iris.unil.ch/handle/iris/152467; serval:BIB_9C48A9CE403D; 000500971000002

Dostupnosť: https://iris.unil.ch/handle/iris/152467
https://doi.org/10.1186/s40425-019-0818-3

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Autori: Lebbé, Celeste Meyer, Nicolas Mortier, Laurent a ďalší

Zdroj: J Clin Oncol
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998

Predmety: Adult, Male, Skin Neoplasms, Time Factors, Medizin, Antineoplastic Agents, Drug Administration Schedule, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Agents, Immunological/administration & dosage, Double-Blind Method, Immunological/administration & dosage, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Melanoma/drug therapy, Ipilimumab/administration & dosage, Melanoma, Aged, Neoplasm Staging, Aged, 80 and over, 2. Zero hunger, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Ipilimumab, Progression-Free Survival, Nivolumab/administration & dosage, 3. Good health, Nivolumab, Disease Progression, Female, Rapid Communication

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30811280
https://hdl.handle.net/20.500.12530/76708
https://pubmed.ncbi.nlm.nih.gov/30811280/
http://europepmc.org/article/MED/30811280
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.18.01998
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455714
https://ascopubs.org/doi/10.1200/JCO.18.01998
https://moh-it.pure.elsevier.com/en/publications/evaluation-of-two-dosing-regimens-for-nivolumab-in-combination-wi-3
https://curis.ku.dk/ws/files/236508642/jco.18.01998.pdf

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice

Autori: Dongmin Jung Chang Young Lee Byoung Chul Cho a ďalší

Prispievatelia: Dongmin Jung Chang Young Lee Byoung Chul Cho a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Adult, Male, Real-worldsetting, Lung Neoplasms, Survival, Original Article – Clinical Oncology, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Non-Small-Cell Lung/drug therapy, Antibodies, Monoclonal, Humanized, Antibodies, Programmed Cell Death 1 Receptor/immunology, 03 medical and health sciences, Lung Neoplasms/immunology, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immunological/administration & dosage, Carcinoma, Non-Small-Cell Lung, Monoclonal, PD-1, 80 and over, Lung Neoplasms/pathology, Humans, Lung Neoplasms/drug therapy, Aged, Retrospective Studies, Aged, 80 and over, Carcinoma, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Middle Aged, Non-smallcelllungcancer, Nivolumab/administration & dosage, 3. Good health, Nivolumab, Treatment Outcome, Non-Small-Cell Lung/immunology, Humanized/administration & dosage, Female, Immunotherapy, Non-Small-Cell Lung/pathology

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00432-019-02899-y.pdf
https://pubmed.ncbi.nlm.nih.gov/30911841
https://link.springer.com/article/10.1007%2Fs00432-019-02899-y
https://europepmc.org/article/MED/30911841
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527531
https://link.springer.com/content/pdf/10.1007/s00432-019-02899-y.pdf
https://ir.ymlib.yonsei.ac.kr/bitstream/22282913/170301/1/T201902062.pdf
https://yonsei.pure.elsevier.com/en/publications/comprehensive-analysis-of-the-characteristics-and-treatment-outco

Dose-dependent toxicity of ipilimumab in metastatic melanoma

Autori: Olischewsky, Alexandra De Schrijver, Sofie Bankfalvi, Agnes a ďalší

Prispievatelia: Olischewsky, Alexandra De Schrijver, Sofie Bankfalvi, Agnes a ďalší

Zdroj: European journal of cancer

Predmety: Male, 0301 basic medicine, Adolescent, Dose-Response Relationship, Drug, Maximum Tolerated Dose, Gastrointestinal Diseases/chemically induced, Medizin, Nivolumab/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Unknown Primary/drug therapy, Skin Neoplasms/drug therapy, Humans, Melanoma/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Ipilimumab/administration & dosage, Human medicine, Neoplasm Metastasis

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/29477367/
https://www.ncbi.nlm.nih.gov/pubmed/29477367
https://hdl.handle.net/10067/1525460151162165141
https://hdl.handle.net/20.500.14017/c8c32dc5-c30f-478e-b1c5-9b680d7e38fe
https://biblio.vub.ac.be/vubir/dosedependent-toxicity-of-ipilimumab-in-metastatic-melanoma(c8c32dc5-c30f-478e-b1c5-9b680d7e38fe).html
https://doi.org/10.1016/j.ejca.2018.01.088
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85042186995
https://www.ncbi.nlm.nih.gov/pubmed/29477367
https://doi.org/10.1016/j.ejca.2018.01.088

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England

Autori: Yang Meng Nadine Hertel John Ellis a ďalší

Zdroj: Meng, Y, Hertel, N, Ellis, J, Morais, E, Johnson, H, Philips, Z, Roskell, N, Walker, A & Lee, D 2018, 'The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England', The European Journal of Health Economics, vol. 19, no. 8, pp. 1163-1172. https://doi.org/10.1007/s10198-018-0964-4

Predmety: Male, Imidazoles/economics, Cost-Benefit Analysis, Antineoplastic Agents, Economic, Kaplan-Meier Estimate, Disease-Free Survival, 03 medical and health sciences, Sex Factors, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Agents, Immunological/administration & dosage, Immunological/administration & dosage, Models, Proto-Oncogene Proteins B-raf/genetics, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Humans, Melanoma/drug therapy, Oximes/economics, Melanoma, Aged, Vemurafenib/economics, Age Factors, Imidazoles, Dacarbazine/economics, Ipilimumab/economics, Middle Aged, Ipilimumab, Markov Chains, Nivolumab/administration & dosage, 3. Good health, Dacarbazine, Models, Economic, Health Resources/economics, Disease Progression, Health Resources, Female, Quality-Adjusted Life Years, Health Expenditures, Antineoplastic Combined Chemotherapy Protocols/economics

Popis súboru: application/pdf

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007%2Fs10198-018-0964-4.pdf
https://pubmed.ncbi.nlm.nih.gov/29524005
https://eprints.gla.ac.uk/159413/1/159413.pdf
https://www.ncbi.nlm.nih.gov/pubmed/29524005
https://ideas.repec.org/a/spr/eujhec/v19y2018i8d10.1007_s10198-018-0964-4.html
https://link.springer.com/article/10.1007/s10198-018-0964-4/fulltext.html
https://europepmc.org/article/MED/29524005
https://link.springer.com/content/pdf/10.1007%2Fs10198-018-0964-4.pdf
https://core.ac.uk/display/153546381